On-treatment progression-free survival analysis of aflibercept-FOLFIRI treatment within 28 days of progression in metastatic colorectal cancer: Updated efficacy results from the VELOUR study.
David Raymond Ferry
Consultant or Advisory Role - Regeneron; Sanofi
Honoraria - Regeneron; Sanofi
Tae Won Kim
No relevant relationships to disclose
Tormod Kyrre Guren
No relevant relationships to disclose
Jayesh Desai
Consultant or Advisory Role - Sanofi
Luis Marcelo Villanueva
No relevant relationships to disclose
Michael L. Andria
Employment or Leadership Position - Regeneron
Eric Van Cutsem
Research Funding - Sanofi
Josep Tabernero
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Genentech; Merck KGaA; Millennium; Novartis; Onyx; Pfizer; Roche; Sanofi
Honoraria - Amgen; Merck KGaA; Novartis; Roche; Sanofi